Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | DGKA | P23743 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2099463 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL16719229 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL31240235 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL16323750 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL17296020 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL8033386 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL25168218 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL8507410 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL22029385 | 1.00 | TDP1 (0.53) | TDP1GPR84FFAR1FFAR4EPHX2 | |
| SCHEMBL934152 | 0.98 | TDP1 (0.50) | TDP1GPR84FFAR1FFAR4EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4746969-A1 | HETEROCYCLIC PAD4 INHIBITORS | Bristol-Myers Squibb Company (US) | 2026-05-27 | — | — | EP | disclosed |
| WO-2025024288-A1 | HETEROCYCLIC PAD4 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-11-07 | — | — | US | disclosed |
| EP-4392420-A1 | HPK1 DEGRADERS, COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME | BIOFRONT LTD (KY) | 2024-07-03 | — | — | EP | disclosed |
| US-12024484-B2 | Lipid formulations for gene editing | VERVE THERAPEUTICS, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-20240131169-A1 | CLIPTAC COMPOSITION | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-04-25 | — | — | US | disclosed |
| CN-117858874-A | HPK1 degrading agents, compositions comprising the same, and methods of use thereof | 百放开曼有限公司 | 2024-04-09 | — | — | CN | disclosed |
| US-11786600-B2 | Cliptac composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11786600-B2 | Cliptac composition | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-10-17 | — | — | US | disclosed |
| US-11746086-B2 | Non-aggregating heptamethine cyanine fluorophores for in vivo imaging | THE USA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-09-05 | — | — | US | disclosed |
| US-8741884-B2 | Compounds for the treatment of hepatitis C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-06-03 | — | — | US | disclosed |
| US-8394829-B2 | Bi-functional quinoline analogs | GILEAD SCIENCES, INC. (US) | 2013-03-12 | — | — | US | disclosed |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC (US) | 2013-01-10 | — | — | US | disclosed |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | SEQUOIA PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | disclosed |
| US-20120093767-A1 | Compounds for the Treatment of Hepatitis C | BRISTOL-MYERS SQUIBB COMPANY | 2012-04-19 | — | — | US | disclosed |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | GILEAD SCIENCES, INC. (US) | 2011-11-10 | — | — | US | disclosed |
| US-7560484-B2 | Vaccine preparation containing fatty acid as a constituent | THE KITASATO INSTITUTE (JP) | 2009-07-14 | — | — | US | disclosed |
| US-7560484-B2 | Vaccine preparation containing fatty acid as a constituent | THE KITASATO INSTITUTE (JP) | 2009-07-14 | — | — | US | disclosed |
| US-20040024058-A1 | Vaccine preparation containing fatty acid as component | THE KITASATO INSTITUTE (JP) | 2004-02-05 | — | — | US | disclosed |
| EP-1316314-A1 | VACCINE PREPARATION CONTAINING FATTY ACID AS COMPONENT | THE KITASATO INSTITUTE (JP) | 2003-06-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024058-A1 | Vaccine preparation containing fatty acid as component | ALOX5, ALOX15B, ALOX15 | TDP1 4718/4885GPR84 618/4885FFAR1 16/4885 |
| US-12024484-B2 | Lipid formulations for gene editing | LIPA, LIPC, ABHD16A | TDP1 1917/4885GPR84 3541/4885FFAR1 1210/4885 |
| US-20110275622-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, MRGPRX2 | TDP1 3985/4885GPR84 300/4885FFAR1 344/4885 |
| US-20120093767-A1 | Compounds for the Treatment of Hepatitis C | HAVCR2, SLC10A1, HCCS | TDP1 3844/4885GPR84 2428/4885FFAR1 2459/4885 |
| US-11746086-B2 | Non-aggregating heptamethine cyanine fluorophores for in vivo imaging | CNDP2, MSN, CHAT | TDP1 1473/4885GPR84 810/4885FFAR1 1031/4885 |
| US-20130012504-A1 | BI-FUNCTIONAL QUINOLINE ANALOGS | BDKRB2, BDKRB1, HRH2 | TDP1 4191/4885GPR84 199/4885FFAR1 263/4885 |
| US-20240368159-A1 | HPK1 DEGRADERS, COMPOSITIONS COMPRISING THE HPK1 DEGRADER, AND METHODS OF USING THE SAME | HYPK, PGK1, HIPK1 | TDP1 1282/4885GPR84 3600/4885FFAR1 3109/4885 |
| US-20120141414-A1 | Bimacrocylic HCV NS3 Protease Inhibitors | HAVCR2, CTRC, CTSC | TDP1 3410/4885GPR84 4071/4885FFAR1 4403/4885 |
| US-11786600-B2 | Cliptac composition | UBE3C, CBLC, STUB1 | TDP1 2806/4885GPR84 2875/4885FFAR1 3976/4885 |
| US-20240131169-A1 | CLIPTAC COMPOSITION | UBE3C, CBLC, STUB1 | TDP1 2806/4885GPR84 2875/4885FFAR1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.